Document is current
Any future updates will be listed below
-
Authors
Wang, Shijie
Kelly, Kaela
Brotchie, Jonathan M.
Koprich, James B.
West, Andrew B. https://orcid.org/0000-0002-3034-4061
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (U01 NS097028, R01 NS064934)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
Atuka, Inc.
- License Information
-
More Information
Article History
Received: 11 October 2019
Accepted: 5 October 2020
First Online: 13 November 2020
Competing interests
: S.W. and K.K. declare no competing conflicts of interest. J.B.K. has received consultancy payments and holds equity stake in Atuka Ltd., Atuka Inc, and Junaxo Inc. J.M.B. has received received consultancy payments from Atuka Inc. A.B.W. receives research support from the Michael J. Fox Foundation for Parkinson’s disease Research, from the National Institutes of Health, from Biogen, Inc, and from eScape Bio, Inc. These funders did not have a role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. A.B.W. is employed by Duke University while engaged in the research project. A.B.W. has received consultation fees from GlaxoSmithKline and eScape Bio, Inc, and is a current member of the Executive Scientific Advisory board at Michael J. Fox Foundation for Parkinson’s Disease Research. A.B.W. is part owner of patent WO2017106771A1 “Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof”.
